19:14 , May 20, 2019 |  BC Extra  |  Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Keytruda fails in previously treated TNBC  Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the...
23:17 , May 10, 2019 |  BioCentury  |  Politics, Policy & Law

The unsung public policy innovators paving the path to cures

Patients with diseases like hemophilia, spinal muscular atrophy and β-thalassemia that could be cured with gene or cell therapies probably don’t know it, but their fates depend as much on the success of public policy...
22:48 , Apr 16, 2019 |  BC Extra  |  Company News

Flagship's Kintai debuts with small molecule microbiome mimic platform, CEO Tak

Kintai Therapeutics Inc. (Cambridge, Mass.) emerged from stealth mode Tuesday, defining Flagship Pioneering's fourth angle on microbiome-based therapeutics. The biotech's orally bioavailable small molecules mimic interactions between the microbiome and host cells to drive therapeutic...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
13:36 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Aerpio's Tie2 activator fails diabetic retinopathy trial

Aerpio said twice-daily 15 mg subcutaneous AKB-9778 missed the primary endpoint in the Phase IIb TIME-2b trial to treat moderate-to-severe non-proliferative diabetic retinopathy. AKB-9778 is a tyrosine kinase receptor 2 (Tie2) activator. On the primary...
01:17 , Mar 13, 2019 |  BC Extra  |  Company News

FDA approves Aerie glaucoma therapy Rocklatan

Aerie said late Tuesday FDA approved Rocklatan netarsudil/latanoprost to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product is a fixed-dose combination of Aerie's Rhopressa netarsudil 0.02%, a dual inhibitor of...
23:42 , Jan 3, 2019 |  BC Innovations  |  Targets & Mechanisms

Getting kumbaya with infections

Up-and-comer Janelle Ayres is flipping the script on antibiotic resistance with a strategy to convert bacteria from virulent pathogens into benign members of the microbiome and turn infectious diseases into harmless conditions. The idea is...
00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...